Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01 – Phase 1 Trial to Evaluate ZT-01 for the Prevention of Insulin-Induced Hypoglycemia in Patients with Type 1 Diabetes – Toronto, Canada, September 29, 2020 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low […]
Zucara Therapeutics Announces US$21 Million Series A Financing – Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials – – Series A Financing led by the Perceptive Xontogeny Venture Fund – Toronto, Canada, March 31, 2020 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced […]
TORONTO and VANCOUVER, CANADA (January 12, 2016) — A novel drug therapy to reduce the severity and frequency of hypoglycemic (low blood sugar) episodes in people with diabetes is being developed by Zucara Therapeutics Inc. This new start-up company, created by MaRS Innovation and The Centre for Drug Research and Development (CDRD) is based on […]